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Abstract
Introduction: Hyper- and hypothyroidism are accompanied by altered metabolic rate, thermogenesis, and body weight. The aim of this 
study was to estimate the relation between treatment-induced changes in thyroid function, and the accompanying body composition in 
patients with either severe hypo- or hyperthyroidism. 
Material and methods: Body composition analysis and hormonal assessment were measured at the initial diagnosis of thyroid disorder, 
after three-month treatment, and finally after complete recovery from hyperthyroidism (n = 18) or hypothyroidism (n = 27). Nonparametric 
Spearman correlation was used to analyse the relation between thyroid hormones and body composition as well as their respective changes.
Results: In hypothyroid patients applied treatment significantly reduced (p < 0.05) total body weight, mainly due to a decrease in fat 
mass, whereas in hyperthyroid patients it caused a weight gain, with a simultaneous increase in muscle, water and fat mass. Total body 
weight and fat mass were significantly correlated with thyroid hormones’ concentrations in all patients. Changes of fat, water, or muscle 
mass were strongly correlated with the changes in the patients’ hormonal status. 
Conclusions: Body composition is related to the concentration of thyroid hormones in thyroid dysfunction. Treatment-induced changes 
in thyroid hormones concentrations are correlated with the magnitude of the change of body weight, including muscle, water, and fat 
amount. (Endokrynol Pol 2016; 67 (4): 359–366)
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Streszczenie
Wstęp: Zarówno nadczynność, jak i niedoczynność tarczycy charakteryzują się zaburzeniami podstawowej przemiany materii, termo-
genezy oraz masy ciała. Celem pracy była ocena związku między zmianami funkcji tarczycy oraz zmianami składu tkankowego ciała 
u pacjentów w trakcie terapii ciężkich zaburzeń funkcji tarczycy.
Materiał i metody: Badanie składu ciała oraz badanie biochemicznych wykładników funkcji tarczycy przeprowadzono u 18 chorych 
z pełnoobjawową nadczynnością tarczycy oraz u 27 chorych z niedoczynnością tarczycy, w okresie rozpoznania choroby, po około trzech 
miesiącach leczenia oraz po całkowitym wyrównaniu funkcji tarczycy, w okresie eutyreozy. Ponadto przeprowadzono analizę związku 
między zmianami funkcji tarczycy oraz zmianami w składzie ciała przeprowadzono nieparametryczną analizę Spearmana.
Wyniki: W grupie chorych leczonych z powodu niedoczynności tarczycy zaobserwowano statystycznie istotny spadek masy, głównie 
kosztem masy tkanki tłuszczowej (p < 0,05), podczas gdy w grupie chorych z pierwotnie rozpoznaną nadczynnością tarczycy stwier-
dzono istotny wzrost masy tkanki tłuszczowej, mięśniowej oraz wody całkowitej (p < 0,05). W obu grupach zaobserwowano ponadto 
istotne korelacje między stężeniem hormonów tarczycy a masą tkanki tłuszczowej na wszystkich etapach leczenia (p < 0,05). Jednocze-
śnie zmiany wszystkich parametrów składu tkankowego ciała (∆) silnie korelowały ze zmianami biochemicznych wykładników funkcji 
tarczycy(∆) (p < 0,05). 
Wnioski: W zaburzeniach funkcji tarczycy obserwuje się silne zależności między składem tkankowym ciała a stężeniem hormonów tar-
czycy. Zmiany w składzie tkankowym ciała są jednocześnie silnie skorelowane ze zmianami stężenia hormonów tarczycy obserwowanymi 
w trakcie terapii. (Endokrynol Pol 2016; 67 (4): 359–366)
Słowa kluczowe: skład tkankowy ciała; nadczynność tarczycy; niedoczynność tarczycy; masa ciała
Introduction
Thyroid hormones regulate the metabolism of the 
whole human body — triiodothyronine (T3) is neces-
sary to maintain the energy requirements of various 
cells and tissues, to balance their anabolism and ca-
tabolism, and regulate body weight [1–4]. An abnormal 
amount of T3 disturbs a number of metabolic processes 
[2]: shortage of T3 in hypothyroidism reduces basic 
metabolic rate and thermogenesis, inhibits catabolism 
and gains total body weight [5]; excess of T3 in hyper-
thyroidism reverses these processes [6]. 
Marek Ruchała M.D., Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, 
Poland, e-mail: mruchala@ump.edu.pl
360
PR
A
C
E 
O
RY
G
IN
A
LN
E
Treatment of severe thyroid function disorders and changes in body composition  Adam Stangierski et al.
Specific therapy of hypo- [7, 8] and hyperthyroidism 
[9–11] restores proper body mass. Only a few studies 
have evaluated changes in body composition, i.e. mus-
cle, water, and fat masses induced by thyroid diseases. It 
appears, however, that the relation between body com-
position and thyroid hormones, and particularly their 
respective treatment-induced changes, has not been 
studied so far. We hypothesise that: 1) body composition 
is related to the current status of thyroid hormones, and 
2) the change in body composition is strictly related to 
the change of thyroid hormones concentration caused 
by specific treatment of hypo- and hyperthyroidism. 
The aim of this study was to: 
 —  estimate body muscle, water, and fat mass in pa-
tients with hypo-and hyperthyroidism before and 
during the therapy of thyroid diseases, and after 
restoring euthyroidism; 
 —  analyse the relation between the concentration of 
free-triiodothyronine (fT3), thyroxine (fT4), and 
thyroid stimulating hormone (TSH), and different 
components of body mass; 
 — investigate the association between the changes in 
T3, T4, and TSH, and the changes in the muscle, 
water, and fat mass at different stages of the therapy 
of thyroid diseases.
Material and methods
This observational pilot study included 70 consecutive 
adult patients from our outpatient clinic with an initial 
diagnosis of a naïve hypo- or hyperthyroid disorder. 
The Poznan University of Medical Sciences Ethical Com-
mittee in Poznan, Poland approved the study protocol 
(nr of declaration 161/11; 2011-Feb-11). All patients pro-
vided their informed written consent for participation 
before entering the study. Only the most contemporary 
guideline-based therapy of thyroid diseases according 
to the recommendations of the American Thyroid As-
sociation (ATA) was applied. No experimental treatment 
was allowed. 
The main inclusion criteria were based on the 
current recommendations of the ATA [12–14], i.e. the 
presence of symptoms characteristic for thyroid func-
tion disease:
 — a newly diagnosed hypothyroidism with free T3 
(fT3) < 3.95 pmol/L, free T4 (fT4) <11pmol/L and 
TSH > 4.5 µU/mL) or
 — hyperthyroidism with fT3 > 6.80 pmol/L, fT4 > 21.5 
pmol/L and TSH < 0.27 µU/mL.
Additional requirements were: 
 — completing all visits during the follow-up;
 — a restoration of euthyreosis no later than during the 
third follow-up visit. The following patients were 
excluded from the study: 
 — those with any chronic condition requiring ad-
ditional pharmacological treatment potentially alter-
ing body composition (e.g. diuretics, beta-blockers, 
hypoglycaemic agents, or steroids); 
 —  those with thyroid cancer; 
 —  those with any inflammation potentially affecting 
body composition (based on the clinical evalua-
tion and measurement of C-reactive protein [CRP] 
concentration). 
Study protocol and flow
The study protocol involved hormonal assessment and 
body composition analysis at the initial visit before the 
onset of therapy (Visit 1), after 12–16 weeks (Visit 2), 
and 24–32 weeks (Visit 3), when the euthyroidism was 
anticipated. Study protocol and flow are presented in 
Figure 1.
Body composition analysis
A detailed body composition analysis was performed 
with the use of a total body bioimpedance analyser 
Tanita MC 180 MA II (Tanita, Japan) for the measure-
ment of total body weight, as well as the estimation of 
mass of muscles, water, and fat. All body composition 
measurements were made at each study stage.
Biochemical analysis
A sample of 10 mL of venous blood was collected 
from fasting patients in the morning hours during 
each visit. All patients were asked to refrain from 
smoking and drinking tea or coffee for at least 12 
hours, and from drinking any alcohol for at least 24 
hours before blood sampling. The concentrations of 
TSH, fT3, and fT4 were assessed with the use of the 
Figure 1. Study protocol and flow
Rycina 1. Protokół i przebieg badania
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electrochemiluminescence method (Hitachi COBAS 
e 600, Japan). CRP determination was performed 
with immunoturbidimetry (Roche Diagnostics, Man-
nheim, Germany)
Statistical analysis
Finally, 45 patients, i.e. 18 patients with hyperthyroid-
ism and 27 with hypothyroidism, were included in the 
analysis. The Shapiro-Wilk test showed that the major-
ity of continuous data presented non-normal distribu-
tion. Therefore, all data are described as median and the 
25th and 75th percentile — the interquartile range (IQR). 
Only results for Visit 2 and 3 were compared with the 
results of Visit 1 with the nonparametric Wilcoxon test 
for paired data. For the comparison between patients 
with hyperthyroid and hypothyroid disease the non-
parametric Mann-Whitney test was applied. The non-
parametric Spearman rank test was used to analyse the 
correlations: (1) between the concentrations of fT3, fT4, 
and TSH with components of body mass for pooled data 
(total n = 135 — 3 visits times 45 patients); and (2) be-
tween the changes in hormone concentrations and body 
composition measured between Visit 1 and 2 (n = 45), 
and Visit 2 and 3 (another n = 45) for pooled data (total 
n = 90); p < 0.05 was considered statistically significant. 
Statistical analyses were made with the use of Medcalc 
softwere (version 13.0.4.0) (Medcalc, Belgium). 
Results
Preliminary, there were six male and 22 female patients 
with hyperthyroid disease, with a median age of 36.5 
years (25th–75th percentile: 31–53 years) with an initial 
diagnosis of Graves disease or toxic nodular goitre. 
Methimazole (Thyrozol; Merck, Germany) in a dose 
of 60–80 mg/daily was initially induced during the first 
visit and, based on clinical hormonal evaluation, this 
dose was gradually and individually titrated for each 
patient during control Visit 2. There were also 9 male 
and 33 female patients with hypothyroid disease with 
a median age of 45 years (25th–75th percentile: 31–75 
years old) with chronic and advanced autoimmune 
thyroiditis (Hashimoto disease) or individuals with 
post-ablative 131-iodine induced hypothyroidism. Dur-
ing the initial visit, treatment with levothyroxine (LT4) 
(1.5–2 µg/kg) was started. Depending on the clinical 
state and hormonal assessment during Visit 2, the initial 
dose of LT4 was adequately modified. 
The concentration of CRP was 1.9 mg/L (25th–75th 
percentile: 1.1–2.9 mg/L) in hyperthyroid patients and 
1.4 mg/L (25th–75th percentile: 0.0–2.4 mg/L) in hypothy-
roid individuals at the time of Visit 1. 
Euthyroidism was confirmed during the third 
visit (V3) in 18 patients with hyperthyroidism and in 
27 patients with hypothyroidism. 
Effects of therapy on hormonal status  
and body composition
Hyperthyroid group 
TSH concentration was significantly lower during Visit 1 
than during Visit 2 and 3 (p < 0.005 for all comparisons). 
The concentrations of fT3 and fT4 were significantly 
higher during Visit 1 than during Visit 2 and 3 (p < 0.005 
for all comparisons) (Table I).
Total body mass and fat mass significantly increased 
after the early phase of treatment, while muscle mass 
and total body water were higher compared to the base-
line values after euthyroidism was restored (Table II).
Hypothyroidism group 
TSH concentration was significantly higher during 
Visit 1 than during Visit 2 and 3 (p < 0.0001 for all 
comparisons). The concentrations of fT3 and fT4 were 
significantly lower during Visit 1 than during Visit 2 and 
3 (p < 0.0001 for all comparisons) (Table III).
Total body mass and fat mass significantly decreased 
after the early phase of treatment. There was no signifi-
cant change in the muscle mass and total body water 
during the treatment (Table IV).
Analysis of hormonal profiles revealed that patients 
with hyperthyroid disease, in comparison with hypothy-
roid individuals, had significantly lower concentrations 
of TSH at Visit 1 (p < 0.0001) and 2 (p = 0.026), and signifi-
Table I. Results of hormonal assessment in patients with hyperthyroidism during the whole study
Tabela I. Wyniki badań hormonalnych u pacjentów leczonych z powodu nadczynności tarczycy
Visit 1 Visit 2 Visit 3
Median 25th–75th percentile Median 25th–75th percentile Median 25th–75th percentile
TSH (normal values: 0.28–4.4) [µIU/mL] 0.01 0.01–0.01 0.09* 0.01–17.1 2.6* 1–4.2
fT3 (normal values: 3.95–6.8) [pmol/L] 24.4 19.1–29.2 5.8* 3.9- 8.5 4.7* 4.3–5.7
fT4 (normal values: 11–21.5) [pmol/L] 50.1 39.9–90 9.6* 6.6–20.6 16.1* 13.4–17.4
*p < 0.005 for all comparisons between Visit 2 vs. Visit 1 or Visit 3 vs. Visit 1 for all hormones
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cantly higher concentration of fT3 at Visit 1 (p < 0.0001), 
and fT4 at Visit 1 (p < 0.0001). However, after reach-
ing euthyroidism (Visit 3), hyperthyroid patients had 
significantly lower fT4 concentration (p = 0.003).
Hyperthyroid patients had significantly lower 
body weight (p = 0.0426) and fat mass (0.0132) than 
hypothyroid patients at Visit 1 before the treatment 
was started (Table II and IV). No significant differences 
were observed for the mass of muscles and total body 
water at this time. During Visit 2 and 3 there were no 
significant differences in the total body weight and 
masses of any analysed body compartments. 
Correlations between hormone concentration  
and body composition
At each stage of treatment, whole body weight and 
masses of particular body compartments were corre-
lated with corresponding values of TSH, fT3, and fT4 
concentrations for pooled data of all patients and all 
measurements (total 135 pairs of different correlations). 
TSH was significantly and positively correlated with 
body weight and fat mass but not with muscle mass and 
total body water. Both fT3 and fT4 were significantly and 
negatively correlated only with body weight and fat mass 
but not with muscle mass and total body water (Table V).
Correlations between changes in hormone  
concentration and body composition
Changes in fT3, fT4, and TSH were significantly cor-
related with changes in the body weight and all of its 
analysed contributions, i.e. fat, muscle, and body water 
mass. Changes in both fT3 and fT4 were negatively cor-
related with changes in body weight and fat, muscle, and 
water masses. Changes in TSH were positively correlated 
Table III. Results of hormonal assessment in patients with hypothyroidism
Tabela III. Wyniki badań hormonalnych u pacjentów leczonych z powodu niedoczynności tarczycy
Visit 1 Visit 2 Visit 3
Median 25th–75th percentile Median 25th–75th percentile Median 25th–75th percentile
TSH [µIU/mL] 100 60.6–100 9.6* 2.7–17.9 1.8* 0.6–3.5
fT3 [pmol/L] 2.4 1.8–3 4.5* 3.8–5.5 4.7* 4.2–5.4
fT4 [pmol/L] 3.9 3.2–6.2 16.9* 12.6–19.2 19.5* 16.5–21.2
*p < 0.0001 for all comparisons between Visit 2 vs. Visit 1 or Visit 3 vs. Visit 1 for all hormones
Table IV. Changes in body composition observed during treatment of hypothyroidism
Tabela IV. Zmiany w składzie tkankowym ciała w trakcie terapii niedoczynności tarczycy
Visit 1 Visit 2 Visit 3
Median 25th–75th percentile Median 25th–75th percentile Median 25th–75th percentile
Total body mass [kg] 72.35 62.7–87.5 69.3* 60.4–85.6 68.9 60.5–83.7
Body fat mass [kg] 21.5 16.1–25.4 19.15* 14.7–24.1 20 15.7–25.7
Muscle mass [kg] 47.6 42.8–58.1 46.2 43.2–57.1 47.2 42.7–56.1
Total body water [kg] 35.3 31.4–44.1 34.4 31.7–43,1 35.2 31.5–43
*p < 0.0005 Visit 2 vs. Visit 1;**p < 0.005 Visit 2 vs. Visit 1
Table II. Changes in body composition during treatment of hyperthyroidism
Tabela II. Zmiany w składzie tkankowym ciała w trakcie terapii nadczynności tarczycy
Visit 1 Visit 2 Visit 3
Median 25th–75th percentile Median 25th–75th percentile Median 25th–75th percentile
Total body mass [kg] 61.6 56.7–77.7 65.9* 58.1–79 65.2 59.4–83.5
Body fat mass [kg] 13.4 9.1–18.6 15.3* 10.2–21.2 16.7 10.9–24.6
Muscle mass [kg] 44.1 41.2–52.9 44.7 42.7–54.2 46.2*** 43–55.2
Total body water [kg] 33.1 31.1–40.6 33.9 31.9–40.9 34.7*** 32.5–42.1
*p < 0.0005 Visit 2 vs. Visit 1; **p < 0.005 Visit 2 vs. Visit 1; ***p < 0.05 Visit 3 vs. Visit 1
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with changes in body weight and fat, muscle, and water 
masses. The strongest correlations were observed for 
the relation of changes in hormonal concentrations and 
body weight or fat mass, whereas the weakest was with 
the total water mass (Table VI, Figure 2).
Discussion
In this study we found that in patients with hyperthy-
roid disease, the applied treatment caused a significant 
increase in total body weight as well as the masses of fat, 
muscles, and body water. In subjects with hypothyroid 
disease, the treatment significantly reduced total body 
weight and body fat mass but showed no influence on 
muscle and body water mass. Furthermore, patients 
with hyperthyroid disease had significantly lower body 
weight and fat mass than individuals with hypothyroid 
disease, but only before an appropriate treatment had 
been started. During the treatment and when euthy-
roidism was obtained, there were no statistical differ-
ences in body weight and the masses of muscles, fat, and 
water between both studied groups. The novelty of this 
study is the analysis of the link between concentration 
of fT3, fT4, and TSH and body composition as well as 
between the changes in the hormonal concentrations 
and the changes of body composition. In more detail, 
there were significant correlations between thyroid 
hormonal profile and body weight and fat mass, but not 
with muscle or body water mass. However, the changes 
in body weight and all analysed body compartments, 
i.e. fat, muscle, and water mass, were all significantly 
correlated with the changes in fT3, fT4, and TSH ob-
served during the treatment. For these associations, 
changes in hormones were most strongly related to the 
changes in total body weight and fat mass. 
Most previous studies on this topic compared body 
composition between patients with thyroid function 
disorders and healthy individuals [15–17], which does 
not allow avoidance of the individual metabolic differ-
ences between the subjects, thusly blinding the results. 
In contrast, we compared body composition and its 
change within the same patients, at different stages of 
thyroid disease: in severe thyroid dysfunction, during 
treatment, and after restoring euthyroidism. Few similar 
studies in hyperthyroid patients showed an increase 
of total body weight after 3–24 months of treatment 
[6, 9–11, 18–20], but no details on body compartments 
such as fat, muscle, or water mass were assessed. Few 
other studies in hypothyroid patients revealed either 
a loss or no significant change of total body mass during 
the LT4 replacement therapy [7–9].
It is unknown whether the weight loss in overt 
hyperthyroidism results from decrease in body fat or 
muscle mass. Greenlund et al. [16] and Brunova et al. 
Table V. Correlations between the concentration of TSH and thyroid hormones, and body weight and masses of particular 
body compartments (pooled data, n = 135)
Tabela V. Korelacje między stężeniem TSH i hormonów tarczycy a masą poszczególnych tkanek (dane zbiorcze, n = 135)
fT3 fT4 TSH
rho P value rho P value rho P value
Body weight –0.17 0.05 –0.18 0.03 0.26 0.0021
Fat mass –0.29 0.0007 –0.27 0.0018 0.34 0.0001
Muscle mass –0.04 n.s. –0.07 n.s. 0.13 n.s. 
Total body water mass –0.01 n.s. –0.06 n.s. 0.11 n.s.
Table VI. Correlations between the changes in body composition and changes in thyroid status (pooled data, n = 90)
Tabela VI. Korelacje między zmianami w składzie tkankowym organizmu a zmianami biochemicznych wykładników funkcji 
tarczycy (dane zbiorcze n = 90)
∆fT3 ∆fT4 ∆TSH
rho P value rho P value rho P value
∆body weight –0.67 <0.0001 –0.73 <0.0001 0.76 <0.0001
∆fat mass –0.54 <0.0001 –0.61 <0.0001 0.63 <0.0001
∆muscle mass –0.4 0.0001 –0.41 0.0001 0.48 <0.0001
∆total body water mass –0.37 0.0012 –0.35 0.0008 0.4 0.0001
∆ — change
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[9] reported that overproduction of T3 leads to a similar 
decrease of both fat and free fat mass (FFM). Miyakawa 
et al. pointed out that hyperthyroidism in men mainly 
causes loss of body fat [21]. Thyroid hormones, together 
with growth hormone, catecholamines, glucagon, 
insulin, and others, regulate the metabolism of mus-
cular cells [22–24]. Hyperthyroidism increases protein 
turnover leading to the loss of muscle mass [25], ac-
celerates thermogenesis, and induces gluconeogenesis 
and lipolysis [25–28] by metabolising amino acids from 
muscles and free fatty acids from adipose tissue. These 
metabolic changes result from a constant production of 
energy at an increased level.
Our study shows what happens during restoration 
of the euthyroid state; there is a significant increase of 
all major contributors to the total body mass, i.e. of the 
fat, muscle, and water. In some other studies, the main 
increase of muscle mass during antithyroid therapy was 
Figure 2. Correlations between changes in hormone concentration and changes in body weight, fat mass, muscle mass, and total body 
water in all analysed groups of patients. Pooled data (n = 90) (0 — hyperthyroid group, 1 — hypothyroid group)
Rycina 2. Korelacje między zmianami w składzie tkankowym ciała a stężeniem hormonów tarczycy u wszystkich analizowanych 
pacjentów. Analiza zbiorcza (n = 90) (0 — nadczynność tarczycy, 1 — niedoczynność tarczycy)
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also documented [28]. All these data suggest that the 
anti-hyperthyroid treatment stops further loss of energy 
and restores its potential sources in adipose tissue and 
muscles. In our study, the anti-hyperthyroid therapy 
resulted also in an increase in total body water. Thyroid 
hormones do not influence water and electrolyte bal-
ance directly. However, the accompanying increased 
activity of aldosterone, atrial natriuretic factor [29], 
and adrenergic activation are found in hyperthyroid 
patients. There is also some shift of fluids from extravas-
cular space into the circulation, resulting in an increased 
cardiac output [30] that is typical for hyperthyroidism. 
All these changes result in actual body dehydration. An-
tithyroid therapy reverses these processes and corrects 
hydration. This may explain our findings. For patients 
with hypothyroid disease, body composition changes 
seem to go in another direction. 
Seppel et al. postulate that hypothyroidism induces 
weight gain mainly by increasing adiposity [31] — this 
is in concordance with our findings. Regarding the 
LT4 replacement therapy, Sanchez et al. and Lonn et 
al. noted a significant decrease of fat mass and free 
fatty mass (FFM) after 4–10 months and 3–12 months 
of such treatment, respectively [8, 20]. Karmisholt et al. 
observed a significant decrease in FFM with an unal-
tered fat mass one year after LT4 treatment induction 
[7]. In our study, weight reduction observed during LT4 
therapy (only during the first control visit) was an effect 
mainly of decreased body adiposity. It is probable that 
that LT4 inhibited lipogenesis and enhanced lipolysis 
due to an increased body energy demands and faster 
metabolism. 
Most of the studies describing correlations of thyroid 
hormones with masses of particular body compart-
ments were performed in euthyroid subjects and usu-
ally presented contradictory conclusions. While some 
authors did not reveal any relations between thyroid 
status and body composition [31–32], the others found 
strong positive associations between total body mass 
and TSH/thyroid hormones concentrations [33–35]. 
To our knowledge, this is the first study showing both 
changes in thyroid hormone concentrations and body 
composition in time. We included patients in the symp-
tomatic stage of thyroid disease, during the applied 
treatment, and after restoring euthyroidism. Strong 
associations between hormone concentrations and 
body compartments were shown, and these findings 
indirectly confirm a significant influence of thyroid 
hormones on fat and muscular metabolism. Our results 
also support the hypothesis that the actual thyroid 
status is an indicator of current body adiposity and 
FFM [33, 36, 37]. The limitations of our study must be 
recognised. First, the number of studied patients is not 
large. However, this was a pilot study and its promising 
results convinced us to plan new and more advanced 
future studies in much bigger groups. Second, the fi-
nally analysed groups were quite homogenous — all of 
the subjects had no other accompanying diseases, had 
completed the whole treatment of their disease, and 
had obtained euthyroid state. Another limitation is the 
evaluation of body composition with the use of bioim-
pedance. Although this method may not be as precise 
as gold standard methods such as Dual-energy X-ray 
Absorptiometry (DXA) [38, 39] or magnetic resonance 
imaging (MRI); however, bioimpedance assessment is 
completely noninvasive (i.e. no X-ray), harmless, and 
very cheap. The accuracy of bioimpedance has been 
shown in many clinical and population studies, includ-
ing patients with thyroid dysfunction [40, 41]. Finally, 
we used pooled data of all patients and measurements, 
regardless the type of thyroid disease (hyper-and 
hypothyroidism) and its stage, i.e. before treatment, 
during treatment, and after recovery of normal thyroid 
function. This approach was deliberate for at least two 
reasons: first the statistical power of the analysed group 
has been increased, and second, we might analyse dif-
ferent correlations for much wider range of thyroid hor-
mones concentrations and their changes from very low 
to very high with results of body composition analysis. 
A similar study for selected patients like hyperthyroid or 
hypothyroid disease or separately for different phases 
of the treatment might result in missing some important 
information and overlooking some general trends. 
In conclusion, treatment of severe thyroid function 
disorders significantly changes total body weight and 
body composition. Furthermore, total body weight and 
fat mass are correlated with thyroid hormones and 
TSH. Additionally, the changes in thyroid hormones 
concentration are also strongly linked to the change in 
body composition/weight. 
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